The misguided ethics of crossover trials

Contemporary Clinical Trials

Volumn 37, Issue 2, 2014, Pages 167-169

  Prasad, Vinay ^a   Grady, Christine ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Crossover; Ethics of clinical trials; Trial validity

Indexed keywords

EVEROLIMUS; NEW DRUG; PLACEBO; ANTINEOPLASTIC AGENT;

ARTICLE; CANCER MORTALITY; CANCER RESEARCH; CANCER THERAPY; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); COST CONTROL; COST EFFECTIVENESS ANALYSIS; CROSSOVER PROCEDURE; DRUG EFFICACY; EMPIRICAL RESEARCH; EQUIPOISE; ETHICS; EXPERIMENTAL CHEMOTHERAPY-INDUCED NEUROPATHY; EXPERIMENTAL THERAPY; FOLLOW UP; HUMAN; KIDNEY CARCINOMA; MAINTENANCE CHEMOTHERAPY; ONCOLOGY; OVERALL SURVIVAL; PALLIATIVE THERAPY; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STUDY DESIGN; TUMOR GROWTH; NEOPLASMS; PROCEDURES; REPRODUCIBILITY;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; CROSS-OVER STUDIES; DRUGS, INVESTIGATIONAL; HUMANS; NEOPLASMS; REPRODUCIBILITY OF RESULTS;

EID: 84892447806     PISSN: 15517144     EISSN: 15592030     Source Type: Journal    
DOI: 10.1016/j.cct.2013.12.003     Document Type: Article

References (13)

1. Chan A.-W., Altman D.G. Epidemiology and reporting of randomised trials published in PubMed journals. Lancet 2005, 365:1159-1162.
2. Motzer R.J., Escudier B., Oudard S., et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008, 372:449-456.
3. Korhonen P., Zuber E., Branson M., Holleander N., Yatenau N., Katiskalahti T., et al. Correcting overall survival for the impact of crossover via a rank-preserving structural failure time (RPSFT) model in the RECORD-1 trial of everolimus in metastatic renal-cell carcinoma. J Biopharm Stat 2012, 22:1258-1271.
4. Everolimus for the second-line treatment of advanced renal cell carcinoma April 2011 Accessed June 6, 2013, at. http://publications.nice.org.uk/everolimus-for-the-second-line-treatment-of-advanced-renal-cell-carcinoma-ta219.
5. Smith E.M., Pang H., Cirrincione C., Fleishman S., Paskett E., Ahles T., et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA 2013, 309:1359-1367.
6. Rimawi M., Hilsenbeck S.G. Making sense of clinical trial data: is inverse probability of censoring weighted analysis the answer to crossover bias?. J Clin Oncol 2012.
7. Brown C.A., Lilford R.J. The stepped wedge trial design: a systematic review. BMC Med Res Methodol 2006, 6:54.
8. Flaherty K., Infante J., Daud A., Gonzalez R., Kefford R., Susman J., et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012, 367:1694-1703.
9. Djulbegovic B., Kumar A., Soares H., Hozo I., Bepler G., Clarke M., et al. Treatment success in cancer: new cancer treatment successes identified in phase 3 randomized controlled trials conducted by the National Cancer Institute-sponsored cooperative oncology groups, 1955 to 2006. Arch Intern Med 2008, 168:632-642.
10. Dighiero G., Maloum K., Desablens B., Cazin B., Navarro M., Leblay R., et al. Chlorambucil in indolent chronic lymphocytic leukemia. N Engl J Med 1998, 338:1506-1514.
11. Mateos M.V., Hernandez M.T., Giraldo P., de la Rubia J., de Arriba F., Lopez Corral L., et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med 2013, 369:438-447.
12. Kluin-Nelemans H., Hoster E., Hermine O., Walwski J., Trneny M., Geisler C., et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med 2012, 367:520-531.
13. Amiri-Kordestani L., Fojo T. Why do phase III clinical trials in oncology fail so often?. J Natl Cancer Inst 2012, 104:568-569.